INCB 00928-104: INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders (clinicaltrials.gov) - Oct 2, 2026 - P1/2 | N=84 | Completed | Sponsor: Incyte Corporation | Active, not recruiting ➔ Completed | Trial completion date: Nov 2027 ➔ Sep 2026
Monotherapy • Trial completion • Trial completion date • Anemia • Hematological Disorders • Myelofibrosis • Myeloproliferative Neoplasm • Thrombocytosis
|